SBI Securities’s Pharming Group PHAR Stock Holding History

SBI Securities’s Portfolio PHAR Stock Details PHAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$29	–	4170
2025 Q3	$29	Buy	+2	New	+$25	﹤0.01%	3843

Other funds holding PHAR

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

NSG

Nalls Sherbakoff Group Knoxville, Tennessee $139M AUM 21.16% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities's PHAR Position: Q4 2025 in Review

SBI Securities sold out of Pharming Group (PHAR) in Q4 2025, closing a stake of 2 shares — an estimated $29 sold.

SBI Securities first reported a position in PHAR in Q3 2025 and held it in 1 quarter. The position peaked at $29 in Q3 2025. 11 funds tracked by Wall St. Rank hold PHAR as of Q4 2025.

SBI Securities reported no remaining Pharming Group position as of Q4 2025 after selling out during the quarter.
SBI Securities sold 2 Pharming Group shares in Q4 2025, an estimated $29.
SBI Securities first reported a position in Pharming Group in Q3 2025 and held it in 1 quarter.
SBI Securities's Pharming Group position peaked at $29 in Q3 2025.
11 funds tracked by Wall St. Rank held Pharming Group as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.